453 related articles for article (PubMed ID: 26887348)
61. The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS.
Amikura K; Akagi K; Ogura T; Takahashi A; Sakamoto H
J Surg Oncol; 2018 Mar; 117(4):745-755. PubMed ID: 29194647
[TBL] [Abstract][Full Text] [Related]
62. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
[TBL] [Abstract][Full Text] [Related]
63. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases.
Nash GM; Gimbel M; Shia J; Nathanson DR; Ndubuisi MI; Zeng ZS; Kemeny N; Paty PB
Ann Surg Oncol; 2010 Feb; 17(2):572-8. PubMed ID: 19727962
[TBL] [Abstract][Full Text] [Related]
64. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
65. Critical appraisal of surgical margins according to KRAS status in liver resection for colorectal liver metastases: Should surgical strategy be influenced by tumor biology?
Rhaiem R; Duramé A; Primavesi F; Dorcaratto D; Syn N; Rodríguez ÁH; Dupré A; Piardi T; Fernández GB; Villaverde AP; Rodríguez Sanjuán JC; Santiago RF; Fernández-Moreno MC; Ferret G; Ben SL; Suárez Muñoz MÁ; Perez-Alonso AJ; Koh YX; Jones R; Martín-Pérez E; Kianmanesh R; Di Martino M
Surgery; 2024 Jul; 176(1):124-133. PubMed ID: 38519408
[TBL] [Abstract][Full Text] [Related]
66. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
67. Relevance of CEA and LDH in relation to KRAS status in patients with unresectable colorectal liver metastases.
Connell LC; Boucher TM; Chou JF; Capanu M; Maldonado S; Kemeny NE
J Surg Oncol; 2017 Mar; 115(4):480-487. PubMed ID: 28008623
[TBL] [Abstract][Full Text] [Related]
68. From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis.
Andreatos N; Ronnekleiv-Kelly S; Margonis GA; Sasaki K; Gani F; Amini N; Wilson A; Pawlik TM
Surg Oncol; 2016 Sep; 25(3):332-8. PubMed ID: 27566041
[TBL] [Abstract][Full Text] [Related]
69. Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases.
Margonis GA; Buettner S; Andreatos N; Sasaki K; Ijzermans JNM; van Vugt JLA; Pawlik TM; Choti MA; Cameron JL; He J; Wolfgang CL; Weiss MJ
Ann Surg; 2017 Oct; 266(4):641-649. PubMed ID: 28657938
[TBL] [Abstract][Full Text] [Related]
70. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection.
Passot G; Denbo JW; Yamashita S; Kopetz SE; Chun YS; Maru D; Overman MJ; Brudvik KW; Conrad C; Aloia TA; Vauthey JN
Surgery; 2017 Feb; 161(2):332-340. PubMed ID: 27592215
[TBL] [Abstract][Full Text] [Related]
71. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
[TBL] [Abstract][Full Text] [Related]
72. Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?
Passot G; Kim BJ; Glehen O; Mehran RJ; Kopetz SE; Goere D; Overman MJ; Pocard M; Marchal F; Conrad C; Aloia TA; Vauthey JN; Chun YS;
Ann Surg Oncol; 2018 Jan; 25(1):179-187. PubMed ID: 29071660
[TBL] [Abstract][Full Text] [Related]
73. Colorectal cancer metastatic to the brain: analysis of prognostic factors and impact of KRAS mutations on presentation and outcome.
Nieder C; Hintz M; Grosu AL
Clin Transl Oncol; 2016 Jan; 18(1):88-92. PubMed ID: 26260912
[TBL] [Abstract][Full Text] [Related]
74. Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer.
Huang CJ; Teng HW; Chien CC; Lin JK; Yang SH
PLoS One; 2014; 8(6):e65117. PubMed ID: 23755178
[TBL] [Abstract][Full Text] [Related]
75. Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases.
Angelsen JH; Viste A; Løes IM; Eide GE; Hoem D; Sorbye H; Horn A
World J Surg Oncol; 2015 Dec; 13():328. PubMed ID: 26631156
[TBL] [Abstract][Full Text] [Related]
76. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
77. Review: KRAS mutations are influential in driving hepatic metastases and predicting outcome in colorectal cancer.
Steele CW; Whittle T; Smith JJ
Chin Clin Oncol; 2019 Oct; 8(5):53. PubMed ID: 31597434
[TBL] [Abstract][Full Text] [Related]
78. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.
Sorbye H; Dragomir A; Sundström M; Pfeiffer P; Thunberg U; Bergfors M; Aasebø K; Eide GE; Ponten F; Qvortrup C; Glimelius B
PLoS One; 2015; 10(6):e0131046. PubMed ID: 26121270
[TBL] [Abstract][Full Text] [Related]
79. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer.
Yaeger R; Cowell E; Chou JF; Gewirtz AN; Borsu L; Vakiani E; Solit DB; Rosen N; Capanu M; Ladanyi M; Kemeny N
Cancer; 2015 Apr; 121(8):1195-203. PubMed ID: 25491172
[TBL] [Abstract][Full Text] [Related]
80. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.
Yu HA; Sima CS; Shen R; Kass S; Gainor J; Shaw A; Hames M; Iams W; Aston J; Lovly CM; Horn L; Lydon C; Oxnard GR; Kris MG; Ladanyi M; Riely GJ
J Thorac Oncol; 2015 Mar; 10(3):431-7. PubMed ID: 25415430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
